Arcalyst (rilonacept) is employed to treat a number of the symptoms of rare genetic conditions like Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS).
FCAS and MWS square measure inflammatory disorders within which the body develops bound symptoms while nota identified cause (such as virus, bacteria, or illness). These symptoms embrace fever, chills, fatigue, and joint pain.additional serious symptoms might involve the bones and joints, the central system (deafness, vision loss, mental impairment), or major organs like the kidneys.
Arcalyst might treat or forestall the symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS). However, this medication isn’t a cure for these heritable conditions.
Submit your review
Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at site
body aches or pain
difficulty in breathing
loss of voice
unusual tiredness or weakness
Incidence not known
Bloody or black, tarry stools
cough producing mucus
lower back or side pain
pain or tenderness around eyes and cheekbones
painful or difficult urination
severe stomach pain
shortness of breath or troubled breathing
tightness of chest or wheezing
vomiting of blood or material that looks like coffee grounds
Some of the side effects that can occur with rilonacept may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
Adult patients 18 years and older: Treatment should be initiated with a loading dose of 320 mg delivered as two, 2 mL, subcutaneous injections of 160 mg each given on the same day at two different sites. Dosing should be continued with a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection. ARCALYST should not be given more often than once weekly. Dosage modification is not required based on advanced age or gender. Pediatric patients aged 12 to 17 years: Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as one or two subcutaneous injections with a maximum single-injection volume of 2 mL. Dosing should be continued with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg, administered as a single subcutaneous injection, up to 2 mL. If the initial dose is given as two injections, they should be given on the same day at two different sites. ARCALYST should not be given more often than once weekly.